

Ming Li\* and Susumu Ikehara

Department of Stem Cell Disorders, Kansai Medical University, Hirakata City, Osaka, Japan

**Dates:** Received: 17 November, 2014; Accepted: 21 August, 2015; Published: 24 August, 2015

\*Corresponding author: Ming Li, M.D, Ph.D.  
Department of Stem Cell Disorders, Kansai Medical University, 2-5-1 Shinmachi, Hirakata City, Osaka. 573-1010, Japan. Tel: 81-72-804-2450; Fax: 81-72-804-2454; E-mail: liming@hirakata.kmu.ac.jp

www.peertechz.com

ISSN: 2641-3000

Editorial

## Stem Cell Therapy for Neurodegenerative Diseases

Editorial

### Stem cell therapy for neurodegenerative diseases

Aging-related neurodegenerative disorders mainly include Alzheimer's disease (AD) and Parkinson's disease (PD). AD is the most common form of dementia, which is one of the major causes of disability and dependency in the elderly. Since the pathologic characteristics of AD are beta-amyloid (Abeta) plaques and neurofibrillary tangles (NFT) [1], depleting Abeta should be a useful therapy for AD. Extracellular Cathepsin B is associated with amyloid plaques, and colocalizes with Abeta in regulated secretory vesicles in chromaffin cells in AD brains. One report demonstrated that Cathepsin B reduces the relative abundance of Abeta through limited proteolysis, suggesting that the activation of Cathepsin B could offer a therapeutic strategy for AD [2]. Furthermore, antioxidants such as glutathione and vitamin E have been shown to be related to a reduced risk of AD resulting from a decrease in ROS levels, and protects against lipid peroxidation in the brain [3]. In contrast, PD is a chronic progressive disease, characterized by bradykinesia with tremors or postural instability. Its pathologic features show that dopaminergic neurons are lost in the mid-brain, associated with the activation of microglia [4]. Treatment of PD includes medications such as those used in dopamine replacement therapy, dopamine agonists, and anticholinergics, as well as exercise and physical therapy. All treatments aim to control symptoms but cannot prevent the development of the disease.

Neuroinflammation has been shown to be associated with the neurodegenerative diseases, and microglia have been reported to play an important role in the immune defense system of the central nervous system. Microglia activation and the release of associated inflammatory factors have been reported to contribute to chronic neurodegenerative disorders [5]. Stem cells mainly include embryonic stem cells (ESCs), inducible pluripotent stem cells (iPSCs) and tissue-derived stem cells such as bone marrow, fat tissue and cord blood. Stem cell-derived neurons have the potential to integrate into the existing neural networks of the host brain. Human ESCs appear to increase acetylcholine levels to improve cognition and memory in the animal model [6]. Human iPSCs can differentiate into neural cells, and one report showed that induced iPSCs generated from familial ADs into neurons may increase Abeta42 secretion, suggesting that

these iPSCs provide a potential strategy for the development of drugs against AD [7]. Bone marrow-derived mesenchymal stem cells (MSCs) were able to home on the injured brain and remove Abeta plaques from the hippocampus and to reduce Abeta deposits through the activation of endogenous microglia in an induced AD mouse model [8]. Human umbilical cord-derived MSCs have been shown to improve memory deficits, and reduce Abeta deposition [9]. Moreover, one report showed that dopaminergic neurons can be induced from human ESCs, iPSCs, and non-human primate iPSCs [10]. Another report showed that bFGF promoted human BMMSCs to trans-differentiate into neural like cells in vitro, and to play a therapeutic role in a PD animal model [11]. Human umbilical cord-derived MSCs with overexpression of HGF can improve damaged neurons in PD animal models [12].

AD and PD are the most common forms of dementia in the elderly, and there has been a rapid increase in the number of patients worldwide. Pharmacological therapies for AD and PD are mainly aimed at relieving symptoms, but stem cell therapy has the potential to not only regenerate new neurons and replace damaged neurons but also to modulate the immune system. Advanced stem cell therapy is a potential clinical approach to the treatment of neurodegenerative diseases.

### Acknowledgments

We would like to thank Mr. Hilary Eastwick-Field and Ms. Keiko Ando for their help in the preparation of the manuscript.

### References

- Demuro A, Smith M, Parker I (2011). Single-channel Ca(2+) imaging implicates Abeta1-42 amyloid pores in Alzheimer's disease pathology. *J Cell Biol* 195: 515-524.
- Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, et al. (2006). Anti-amyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. *Neuron* 51: 703-714.
- Mangialasche F, Kivipelto M, Mecocci P, Rizzuto D, Palmer K, et al. (2010) High plasma levels of vitamin E forms and reduced Alzheimer's disease risk in advanced age. *J Alzheimers Dis* 20: 1029-1037.
- Jankovic J (2008) Parkinson's disease: clinical features and diagnosis. *J Neurol Neurosurg Psychiatry* 79: 368-376.
- Heneka MT, Kummer MP, Latz E (2014) Innate immune activation in neurodegenerative disease. *Nat Rev Immunol* 14: 463-477.
- Liu Y, Weick JP, Liu H, Krencik R, Zhang X, et al. (2013) Medial ganglionic eminence-like cells derived from human embryonic stem cells correct learning and memory deficits. *Nat Biotechnol* 31: 440-447.
- Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, et al. (2011) Modeling familial Alzheimer's disease with induced pluripotent stem cells. *Hum Mol Genet* 20: 4530-4539.



8. Salem AM, Ahmed HH, Atta HM, Ghazy MA, Aglan HA (2014) Potential of bone marrow mesenchymal stem cells in management of Alzheimer's disease in female rats. *Cell Biol Int* 38: 1367-1383.
9. Darlington D, Deng J, Giunta B, Hou H, Sanberg CD, et al. (2013) Multiple low-dose infusions of human umbilical cord blood cells improve cognitive impairments and reduce amyloid-beta-associated neuropathology in Alzheimer mice. *Stem Cells Dev* 22: 412-421.
10. Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, et al. (2013) Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. *Stem Cells* 31: 1548-1562.
11. Xiong N, Yang H, Liu L, Xiong J, Zhang Z, et al. (2013) bFGF promotes the differentiation and effectiveness of human bone marrow mesenchymal stem cells in a rotenone model for Parkinson's disease. *Environ Toxicol Pharmacol* 36: 411-22.
12. Liu XS, Li JF, Wang SS, Wang YT, Zhang YZ, et al. (2014) Human Umbilical Cord Mesenchymal Stem Cells Infected with Adenovirus Expressing HGF Promote Regeneration of Damaged Neuron Cells in a Parkinson's Disease Model. *Biomed Res Int* 2014: 909657.

**Copyright:** © 2015 Li M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Citation:** Li M, Ikehara S (2015) Stem Cell Therapy for Neurodegenerative Diseases. *Stud Stem Cells Res Ther* 1(1): 002-003.